Pharmaceutics (Feb 2022)

Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library

  • Angela Lauriola,
  • Elisa Uliassi,
  • Matteo Santucci,
  • Maria Laura Bolognesi,
  • Marco Mor,
  • Laura Scalvini,
  • Gian Marco Elisi,
  • Gaia Gozzi,
  • Lorenzo Tagliazucchi,
  • Gaetano Marverti,
  • Stefania Ferrari,
  • Lorena Losi,
  • Domenico D’Arca,
  • Maria Paola Costi

DOI
https://doi.org/10.3390/pharmaceutics14020391
Journal volume & issue
Vol. 14, no. 2
p. 391

Abstract

Read online

The transcriptional regulators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif) are the major downstream effectors in the Hippo pathway and are involved in cancer progression through modulation of the activity of TEAD (transcriptional enhanced associate domain) transcription factors. To exploit the advantages of drug repurposing in the search of new drugs, we developed a similar approach for the identification of new hits interfering with TEAD target gene expression. In our study, a 27-member in-house library was assembled, characterized, and screened for its cancer cell growth inhibition effect. In a secondary luciferase-based assay, only seven compounds confirmed their specific involvement in TEAD activity. IA5 bearing a p-quinoid structure reduced the cytoplasmic level of phosphorylated YAP and the YAP–TEAD complex transcriptional activity and reduced cancer cell growth. IA5 is a promising hit compound for TEAD activity modulator development.

Keywords